Research Analysts Offer Predictions for LFCR FY2025 Earnings

Lifecore Biomedical, Inc. (NASDAQ:LFCR) – Research analysts at Barrington Research increased their FY2025 earnings per share (EPS) estimates for Lifecore Biomedical in a note issued to investors on Wednesday, January 8th. Barrington Research analyst M. Petusky now anticipates that the company will post earnings of ($0.98) per share for the year, up from their previous forecast of ($0.99). The consensus estimate for Lifecore Biomedical’s current full-year earnings is ($0.99) per share. Barrington Research also issued estimates for Lifecore Biomedical’s FY2026 earnings at ($0.60) EPS and FY2027 earnings at ($0.40) EPS.

Lifecore Biomedical (NASDAQ:LFCR) last posted its earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%.

Several other brokerages have also recently issued reports on LFCR. Craig Hallum raised their target price on Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 22nd. Stephens reissued an “equal weight” rating and set a $6.00 price objective on shares of Lifecore Biomedical in a research report on Friday, January 3rd.

Lifecore Biomedical Trading Down 1.9 %

Shares of LFCR stock opened at $5.80 on Friday. The company has a current ratio of 1.83, a quick ratio of 0.80 and a debt-to-equity ratio of 12.90. Lifecore Biomedical has a 12-month low of $3.68 and a 12-month high of $8.90. The stock has a market capitalization of $213.60 million, a P/E ratio of 72.50 and a beta of 0.98. The firm’s 50 day moving average is $7.05 and its 200 day moving average is $5.82.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Legion Partners Asset Management LLC boosted its position in shares of Lifecore Biomedical by 0.6% during the second quarter. Legion Partners Asset Management LLC now owns 2,968,409 shares of the company’s stock worth $15,228,000 after acquiring an additional 18,182 shares during the last quarter. Geode Capital Management LLC increased its stake in Lifecore Biomedical by 10.3% in the 3rd quarter. Geode Capital Management LLC now owns 597,685 shares of the company’s stock worth $2,948,000 after acquiring an additional 55,703 shares during the last quarter. State Street Corp raised its holdings in shares of Lifecore Biomedical by 10.2% during the 3rd quarter. State Street Corp now owns 334,360 shares of the company’s stock worth $1,648,000 after acquiring an additional 30,916 shares in the last quarter. Marshall Wace LLP boosted its position in shares of Lifecore Biomedical by 87.3% during the 2nd quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock valued at $1,540,000 after acquiring an additional 139,887 shares during the last quarter. Finally, DCF Advisers LLC grew its holdings in shares of Lifecore Biomedical by 2.1% in the second quarter. DCF Advisers LLC now owns 290,684 shares of the company’s stock valued at $1,491,000 after purchasing an additional 6,000 shares in the last quarter. 83.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Lifecore Biomedical news, CEO Paul Josephs acquired 17,000 shares of the stock in a transaction dated Wednesday, January 8th. The shares were acquired at an average cost of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the transaction, the chief executive officer now directly owns 559,717 shares of the company’s stock, valued at approximately $3,212,775.58. The trade was a 3.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 28.21% of the stock is currently owned by insiders.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.